Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Saving cash on a tight budget is possible with the right strategies. Discover effective tips to stretch your dollars further.
22,187 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Tech ETFs split into three paths in 2026: broad mega-cap funds stumble, cybersecurity themes gain ground, and AI infr...
When a director sells shares after a sharp gain, it can spark questions about the stock’s future. This article breaks...
Casey’s General Stores posted stronger fuel margins and a growing Rewards base, lifting investor optimism. Analysts c...
Disney reports stronger-than-expected Q2 2026 results, lifting the stock 8% in early trading as streaming and parks r...
When a board member sells shares, investors watch closely. This article unpacks a recent Arteris insider move, what i...
As interest rates climb, even active managers recalibrate risk. Advocacy Wealth Management recently trimmed a major P...
MSGM's Q1 2026 commentary offers a clearer view of the year ahead for investors. This article decodes the msgm 2026 e...
As AI demand accelerates, Nvidia stands out on a growth-adjusted valuation. Cramer argues the stock is cheaper than p...
PepsiCo beat expectations in Q1 with revenue rising 8.5% and earnings surpassing estimates. International momentum an...
A Warby Parker director recently sold 25,000 shares, triggering questions about insider moves. This article breaks do...
Today’s energy-focused market action shows how volatile solar stocks can be when short-seller whispers collide with b...